Below are the top 10 U.S.-listed Chinese stocks with highest upside potential,
UPDATED TODAY before 4:30 AM ET, based on the difference between current price
and Wall Street analysts average target price. China Education Alliance, Inc.
(NYSE:CEU) has the 1st highest upside potential in this segment of the market.
Its upside is 260.2%. Its consensus target price is $8.50 based on the average
of all estimates. SkyPeople Fruit Juice, Inc. (NASDAQ:SPU) has the 2nd highest
upside potential in this segment of the market. Its upside is 218.6%. Its
consensus target price is $13.00 based on the average of all estimates. NF
Energy Saving Corp (NASDAQ:NFEC) has the 3rd highest upside potential in this
segment of the market. Its upside is 211.7%. Its consensus target price is
$12.50 based on the average of all estimates. NIVS IntelliMedia Technology Group
Inc (NYSE:NIV) has the 4th highest upside potential in this segment of the
market. Its upside is 203.0%. Its consensus target price is $7.00 based on the
average of all estimates. WSP Holdings Limited (NYSE:WH) has the 5th highest
upside potential in this segment of the market. Its upside is 185.7%. Its
consensus target price is $3.00 based on the average of all estimates. Xinyuan
Real Estate Co., Ltd. (ADR) (NYSE:XIN) has the 6th highest upside potential in
this segment of the market. Its upside is 175.5%. Its consensus target price is
$6.67 based on the average of all estimates. China Ritar Power Corp.
(NASDAQ:CRTP) has the 7th highest upside potential in this segment of the
market. Its upside is 163.5%. Its consensus target price is $6.67 based on the
average of all estimates. Sutor Technology Group Ltd. (NASDAQ:SUTR) has the 8th
highest upside potential in this segment of the market. Its upside is 157.7%.
Its consensus target price is $5.00 based on the average of all estimates. China
TransInfo Technology Corp. (NASDAQ:CTFO) has the 9th highest upside potential in
this segment of the market. Its upside is 151.1%. Its consensus target price is
$11.00 based on the average of all estimates. China Nuokang Bio-Pharmaceutical
Inc. (NASDAQ:NKBP) has the 10th highest upside potential in this segment of the
market. Its upside is 147.0%. Its consensus target price is $8.25 based on the
average of all estimates.
No comments:
Post a Comment